Drugmaker NATCO Pharma Limited said on 21 November 2026 that the United States Food and Drug Administration (USFDA) has issued seven observations after inspecting its manufacturing plant at Kothur, Hyderabad, in Telangana. The company disclosed the outcome in a regulatory filing, news agencies PTI and IANS reported.
According to the filing, the USFDA inspection ran from 12 November to 20 November 2026 and ended with the observations being recorded on a Form 483.
What did NATCO Pharma say about the observations?
NATCO Pharma said the seven observations are procedural in nature. The company said it is "confident of addressing these observations comprehensively within stipulated timelines". It did not disclose what the individual observations relate to, and IANS reported that the company does not expect major compliance concerns.
What is a USFDA Form 483?
A Form 483 is a notice the USFDA hands to a company's management at the end of an inspection when its investigators have seen conditions that, in their judgment, may breach the US Federal Food, Drug, and Cosmetic Act. The agency's Form 483 FAQ states that the form "does not constitute a final Agency determination" of whether any condition is a violation.
The USFDA says it weighs the observations together with the inspection report, evidence gathered on site and any response from the company before deciding whether further action is needed. Companies are encouraged to reply in writing with a plan for corrective action and to put that plan into effect promptly.
What happens next?
NATCO Pharma is expected to submit its response to the USFDA within the regulator's timelines, as the company has indicated it will. The agency will then review the company's reply along with the inspection record before deciding on the plant's status. Whether the observations lead to any further regulatory step is not yet known.




